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Your talents should not exceed your virtue 
- Confucius - 
  
ABSTRACT 
 
To understand complex phenotypes, medical research has evolved from the study of 
single genes and proteins to approaches that encompass more comprehensive 
catalogues of molecules. Among the more widely used are genome-wide expression 
and high-throughput genotyping, the latter primarily making use of single nucleotide 
polymorphisms (SNPs) in what has been termed genome-wide association studies 
(GWAS). Because of the scale of the data sets that are being produced, unique 
problems have emerged that necessitate the extensive use of bioinformatics tools. This 
thesis has entailed the analysis of several such large data sets in the context of 
biological pathways and introduces several bioinformatics solutions. Paper III, IV, and 
V deal with this topic. This thesis is primarily oriented around the study of Alzheimer 
disease (AD) and aging. The questions about the etiology of AD are often concurrent 
with questions about the biology of aging. This thesis pursues insight on genomic 
factors pertaining to both inquiries, acknowledging that both the AD state and aging 
itself are complex and multi-factorial. Two constituent papers (I and III) address aging 
and two papers (II and V) deal with genetic models in the study of AD. 
In paper I, we examined the association of age with several genetic markers in the 
insulin degrading enzyme (IDE) and explored possible molecular mechanisms. In 
contrast to women, both age-at-sampling and age-at-death of the males were 
significantly lower in individuals that were heterozygous at genetic loci spanning the 
IDE locus. Plasma insulin levels and the expression levels of the gene were found to be 
higher in those same heterozygous males.  
In paper II, SNPs in 25 genes involved in cholesterol metabolism were tested for 
association with AD and dementia. Genetic markers in a large linkage disequilibrium 
block spanning SREBF1, TOM1L2, and ATPAF2 were significantly associated with 
disease. Gene expression and gene network analyses supported the findings.  
In paper III, we investigated the biological pathway basis of age in human brain and 
lymphocytes. Mitochondrial genes were negatively regulated in both tissue samples, 
while the protein translation genes appeared to decrease in lymphocytes but increase in 
brain. Those observations indicated that there are common themes across tissues, but 
also tissue specific changes in gene regulation. We also examined the genomic 
architecture of the age-regulated genes, and found that the expression of non-compact 
genes tend to decrease with advancing age.  
A large number of genome-wide association studies (GWAS) have now been 
performed over the past few years. In paper IV, we developed a program that automates 
the conversion of SNPs to representative gene lists in order to facilitate the exploration 
of biological pathway in the context of GWAS. 
In paper V, we employed the software developed in study IV to identify biological 
pathways enriched among the genes that were significantly associated from a GWAS of 
AD. Genes involved in intracellular protein transmembrane transport were found to be 
significantly overrepresented. These results highlighted the possibility that TOMM40 
contributes to AD pathology together with other translocases. 
  
Through this thesis, several biological relationships have been identified linking AD 
and aging. Genetic markers in IDE, a gene previously claimed to be associated with 
AD, also associate with age. With advancing age, mitochondrial gene expression 
deteriorates significantly. TOMM40 may contribute the AD pathology, together with 
other genes that encode proteins of the intracellular transmembrane protein transport 
pathway. Methodologically, pathway analyses were conducted successfully with the 
program, ProxyGeneLD. This enabled discoveries and discussion of the challenges that 
face the exploration of GWAS data sets in a pathway context. In the future, more 
sophisticated bioinformatics tools and enhanced gene annotation may lead to the 
discovery of the molecular mechanisms that dominate complex diseases and traits. 
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1 INTRODUCTION 
Alzheimer disease (AD) is the most common cause of the dementia of the elderly, and 
is believed to be induced by large number of factors. Disorders such as Alzheimer 
disease are often termed “complex”, reflecting the challenge of identifying these 
underlying factors. Aging is the single factor that has the largest effect on the onset of 
the disease, and is itself controlled by complex biological mechanisms. Over the past 
decades, a considerable amount of effort has been exerted to understand the link 
between aging and AD.  
In epidemiological studies, the various factors that contribute to a disease are generally 
divided into two groups, genetic and environmental. The genetic factors comprise all 
inherited components that can affect the predisposition of individuals to a disease of 
interest. The environmental factors, complementary and in some respects interacting 
with the genetic component, represent the events an individual is exposed to during 
their lifetime. Examples include both conscious choices like smoking, food preference, 
and degree of physical exercise, but also include chance accidents beyond the control of 
an individual. In this thesis, the various studies have focused primarily only on the 
genetic factors, more specifically single nucleotide polymorphisms (SNPs) that make 
up the majority of the genetic differences that can be found between individuals and 
between human populations.  
These SNPs, also known as genetic variants, in human populations are abundant. They 
occur on average at about 1 site per 1000 DNA. Their relatively high frequency confers 
statistical power for detecting regions of interest in genetic association studies, which 
have been used in several of the papers presented in this thesis. Genetic association 
studies typically entail the examination of SNP (or other kinds of variation) frequency 
in relation to a disease or other phenotype like height or weight. As the technology for 
genotyping (i.e. reading the SNPs in an individual‟s genome) has developed 
dramatically over the past few years, it has become a reality to examine essentially all 
common SNPs in an individual‟s genome using arrays on a single chip. These genome-
wide experiments (also called genome-wide association studies; GWAS) have 
produced enormous quantities of data. Various approaches to understanding this 
genetic data have emerged, and include, apart from the strict assessment of SNP allele 
frequencies for association, attempts at viewing the data in a broader biological context. 
One fundamental approach to investigating the data is to explore for enrichment of 
specific biological pathways among the genes associated with target phenotype. This 
thesis introduces bioinformatics strategies to deal with this research question and 
discusses the issues of such a strategy. 
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2 THE STRUCTURE OF THE HUMAN GENOME 
2.1 SINGLE NUCLEOTIDE POLYMORPHISM (SNP) 
The human genome is the hereditary information of our species stored in long stretches 
of deoxyribonucleic acid (DNA) molecules. The genome is believed to contain all 
information not only for the single cell of a fertilized egg to develop to all of the organs 
that make up the human body, but also for the body to survive in its crude environment. 
These potent molecules are bound into 23 pairs of bundles called chromosomes. Each 
chromosome has a sister chromosome which has ~99.9% identical sequences [7], and 
the pair are called homologous chromosomes. 
Each individual in a population has a unique genomic sequence that differs from every 
other individual [7]. Some of these genetic variants contribute to our physical 
appearance and others influence the onset of the various diseases that afflict us. 
Variations in the genome are classified according to their size and characteristics, and 
include mutation of single bases to large stretches of DNA, to duplications, repeats and 
inversions. By far the most common however is the single nucleotide polymorphism 
(SNP) for which in excess of 10 million are now known to exist across world 
populations [8,9]. SNPs represent the consequence of mutation events that have been 
retained in a population, either by chance or by a selective advantage they confer, that 
has allowed them to attain high frequency. 
The SNP is a single DNA base difference in the genome that consists of two “alleles” 
on the two sister chromosomes. Some individuals will be homozygous whichever the 
common allele at the SNP site, some individuals will be homozygous for the “rarer” 
allele, and some individuals will be heterozygous, having each of the two alleles. From 
the various large-scale genotyping projects conducted around the world in different 
populations, SNPs can be found at a rate of about once every ~1000 bases on average 
when two chromosomes are compared [7-10].  
 
2.2 LINKAGE DISEQUILIBRIUM (LD) 
The information in the human genome is transmitted to each next generation beginning 
with an elaborate molecular system that copies and delivers the DNA in the process of 
meiosis. During this process, the two copies of each chromosome undergo 
recombination, in which long segments of DNA cross over from one chromosome to 
the corresponding position on its sister chromosome. On an extended time-scale, the 
recombination event is rather infrequent, arising on average only once for every stretch 
of approximately 1 million base pairs of DNA per 100 generations [11,12]. Thus, a 
long DNA sequence including all of the mutations that have occurred in that specific 
genomic region (many of them possibly increasing disease risk) tends to be intact while 
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it descends through many generations (an example of a single mutation and its fate 
through multiple generations is depicted in (Figure 1). Figure 1 represents the 
cornerstone of all genetic association studies, which rely on LD to be able to observe 
latent effects of un-genotyped genetic sequence variants. Thus, through recombination, 
the “alleles” located in the vicinity of a spontaneous mutation event are physically 
paired with the allele generated by the mutation, and the correlation is detectable in the 
extant chromosomes that are present today [3]. This is one of the possible mechanisms 
that creates linkage disequilibrium (LD), which can more formally be defined as non-
random association between two or more proximal genetic variants [13]. There are 
diverse other mechanisms that can generate LD, including subpopulation mixing [14] 
and inbreeding [15,16]. Another important aspect of LD is that it tends to decay over 
time. Thus, once established, LD begins to decay by recombination toward an 
equilibrium state, where each subsequent generation has a chance of proximal alleles 
becoming physically detached. This decay rate has been estimated to be about 10-8 per 
base pair per generation [17,18]. In other words, diminishing LD is a relatively slow 
process (proportional to recombination) and so young populations derived from small 
founder groups of people, will tend to have more LD than old populations that have 
been mating amongst themselves for thousands of years. 
One of the commonly used statistics to describe LD between two SNPs is r
2
, which is 
the correlation coefficient of allele frequencies of the two variants. When there are two 
bi-allelic (two alleles) SNPs with alleles “A”, “a” at the first position and “B”, “b” at 
the second position, the value can be calculated as depicted below [13,19]:  
   
          
 
                
 
Figure 1. Preserved linkage 
disequilibrium surrounding ancestral 
mutation. A mutation occurred on the 
chromosome of common ancestor is 
indicated by red triangle. Light blue 
bars represent intact fragments 
transmitted from the ancestral 
chromosome, while dark blues are the 
parts from foreign individuals.  
Reprinted by permission from Macmillan 
Publishers Ltd:  Nature Review Genetics 
(L. Kruglyak[3]), copyright (2008) 
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Where     is the frequency of observation of both AB, and    and    are the 
frequencies of A and B allele respectively.  
A large international effort with the goal of pursuing a LD map of the human genome 
was initiated in October 2002. The effort was termed the International HapMap project, 
and in its first phase successfully genotyped 1.1 million SNPs in 90 human individuals 
from 30 families who lived in Utah with Northern and Western European ancestry from 
the Centre d‟Etude du Polymorphisme Humain collection (abbreviated to CEU) 
together with genotypes of Nigerian, Chinese, and Japanese samples during this first 
phase of the project [17]. During the second phase, an attempt was made to expand the 
number of tested SNPs, this time to include 3.9 million putative polymorphic variants 
for which genotyping assays could be developed [12]. Approximately one third of all 
these tested markers turned out to be non-polymorphic among the CEU samples. The 
remaining confirmed 2.6 million SNPs reflect a distribution across the human genome 
and they are estimated to cover 92% of hidden common variants (minor allele 
frequency ≥ 5%) at the threshold of r2 ≥ 0.8 by pairwise LD. 
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3 GENETIC ASSOCIATION STUDY 
3.1 VOCABULARY IN GENETIC ASSOCIATION STUDIES 
A locus (plural form is loci) is the position of a gene or a genetic variant on a specific 
chromosome. An allele is defined as each different version on a single chromosome of 
a genetic marker of which the variation exists in the population [20]. Since humans 
have two sets of chromosomes (homologous or “sister” chromosomes), each individual 
has two alleles at a single locus. The two collectively form the genotype of an 
individual for that locus. Between the two, the allele for which the frequency in the 
population of interest is larger is commonly known as the major allele and the other is 
minor allele. The frequency of the minor allele is often abbreviated to MAF (minor 
allele frequency) indicating how rare the allele or the genetic variant is. An individual 
having the same alleles at single locus is termed homozygous and an individual having 
different alleles is termed heterozygous.  
When a genetic marker, usually SNP, is in high LD (often r
2≥0.8) with another marker, 
each is called a “proxy” of the other. Especially, if the correlation coefficient is 1, they 
are termed as “perfect proxies”[21]. A Phenotype is defined as specific detectable 
characteristics of an organism [22]. Penetrance is defined as the probability that a 
particular allele or genotype induces a particular phenotype [20]. 
Under the assumptions of random mating with evenly distributed fertilities, no selective 
influx or efflux such as migration or natural selection, and no mutation in a large 
population, the allele and genotype frequencies at a locus will be unchanged through 
generations [23,24]. This equilibrium status is called Hardy-Weinberg equilibrium 
(HWE) [25], in which the genotype frequency of homozygotes is expected to be the 
square of the allele frequency, while the frequency of heterozygotes is simply the 
product of both allele frequencies. The test for HWE of a SNP is commonly performed 
with an asymptotic χ2 test or exact texts [26,27]. 
 
3.2 GENETIC ASSOCIATION STUDY 
Genetic association studies involve the investigation of the potential of a correlation 
between allelic or genotypic variation and phenotypic differences [28,29]. When the 
frequency of a certain variant is observed, for example, in cases at a significantly higher 
level than controls, it can be concluded that there is association between the genetic 
marker and the disease status, and that the specific allele at higher frequency may have 
a contributory role in the disorder. This significance is most appropriately assessed by 
statistical methods, some of which are described in section 7.  
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In contrast with other association studies in general, genetic studies carry the inherent 
difficulty of needing to take into account the extensive correlation that can exist 
between nearby markers due to LD structure. LD is a two-edged sword in that it aids in 
the search for association between genetic marker and phenotype, since genotyping 
proxies can be sufficient to observe association instead of specifically examining the 
precise functional SNP(s) (Figure 2) [6,30,31]. However, on the other hand, the 
association found between a genotype at one locus and phenotype does not denote that 
the tested marker is itself functional. Thus, the functional SNP or other form of 
variation that contributes to the difference in phenotype variance can be any genetic 
variant for which the frequency is highly correlated with the tested marker. This 
contributes to one of the greatest difficulties in attributing “marker associations” to 
“gene associations” since the region of study can extend across numerous gene targets, 
each of which can be a valid biological target in the disease under study. This fact 
should be taken into consideration in any genetic association study. 
 
Figure 2. Testing genetic variant for association directly or indirectly. 
The reds indicate genotyped markers and the blue is the marker in high 
LD with the reds. a. A candidate genotype is directly tested for 
association. b. Utilizing LD structure, the proxies of the candidate are 
genotyped and the association is imputed. 
Reprinted by permission from Macmillan Publishers Ltd:  Nature Review 
Genetics (J. Hirschorn [6]), copyright (2005) 
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4 GENE EXPRESSION MEASUREMENT 
4.1 BIOLOGICAL MATERIAL AND ITS PREPARATION 
The molecules that carry out most of cell functions are proteins, which are encoded in 
the genome and are under sophisticated control. When a cell requires the creation of a 
particular protein, the production is initiated by a process called “transcription”, in 
which an enzyme complex reads the DNA code for a gene of the protein and produces 
messenger RNA (mRNA) which will eventually be converted to a functional protein. 
Since a single DNA sequence can be used as a template for thousands of protein 
molecules, the number of mRNAs is under careful regulatory control, where numerous 
factors act both by binding to genomic DNA and to the produced mRNA. In this thesis, 
“gene expression” refers to the mRNA expression as widely accepted to reflect the 
fundamental mechanism of moving from DNA sequence to the quantity of mRNA. 
Another key concept in the regulation of mRNA is splicing, which refers to the way in 
which the mRNA is processed after being transcribed from DNA. This involves the 
change in the exon structure of an mRNA, where complete exons may be skipped, new 
exons included, or changes induced between exons. This is regarded as a key way in 
which nature and evolution have led to a vast increase in molecular diversity, since the 
number of splice-forms of an mRNA can be on the order of hundreds. 
mRNA as extracted from human tissue samples is chemically too unstable to be used 
directly in the experiments to measure its quantity. To avoid degradation, the material 
containing these fragile molecules should be frozen immediately after acquisition and 
stored in deep freeze (-80°C) [32]. If it is obtained from the tissue that may include 
living cells, this is even more important since cells may react to environment changes, 
possibly activating mRNA degradation machinery, or even promoting the rapid 
production of mRNA as a defense mechanism [33]. Thus as for samples obtained after 
death, for example, brain autopsy samples, the time that has elapsed since death (post 
mortem interval; pmi) to sample treatment should be minimized. Often this kind of 
variation among samples is interrogated in the analysis and documented and thus can 
be used as a covariate in statistics. However, if pmi is less than 48 hours, it affects RNA 
less than agonal status (the period with serious illness before death) [34,35]. To be 
quantified, RNA is usually reverse-transcribed (opposite process of transcription) to 
complementary DNA (cDNA). The most common external cause of mRNA 
degradation is RNAse protein molecules that exist in the environment both from 
humans and other organisms. RNAse proteins are abundant and a single drop of human 
sweat can contain millions that are all capable of rapidly degrading mRNA. This is one 
of the key reasons for converting mRNA rapidly to cDNA for further analysis. 
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4.2 QUANTITATIVE PCR 
The Polymerase Chain Reaction (PCR) is arguably one of the most well known 
molecular biology tools, and was invented to facilitate the amplification of a particular 
DNA sequence by doubling the number of fragments of the sequence in each cycle. It 
has high fidelity and specificity in this amplification reaction, given known flanking 
genetic sequences around a target sequence of interest. A particular sequence can be 
selectively amplified in the mixture of a tremendous number of heterogeneous 
sequences, For example, this might involve all human cDNA sequences in a solution 
perhaps including twenty thousand different molecules, each with millions of copies. 
Because of these features, PCR frequently serves as a tool to obtain both strong 
evidence of the existence of a certain sequence in a DNA sample, as well as to amplify 
existing sequences to achieve large enough quantities for subsequent analyses. 
Additionally, PCR can be also serve to measure the quantity of selected fragments in 
the DNA samples with high specificity by adding special fluorescent dye-attached 
probe and detecting emitted signal from it [36,37]. The method is called quantitative 
PCR (qPCR) or real-time PCR since it can track how much DNA was amplified in each 
cycle. The light intensity from the probe is proportional to the number of amplified 
fragments by PCR, and the amplification speed at same cycle is proportional to the 
initial quantity of the target DNA fragment. So, the quantity in the sample is postulated 
from a surrogate measure, Ct value. The Ct (threshold cycle) is the cycle number at the 
point where the signal intensity exceeds a selected threshold. The threshold is often 
chosen as the intensity value at the centre in the span of noise and highest level on a log 
scale. As an illustration, a signal change graph from a real experiment is shown in 
0,1
1
10
100
1000
10000
0 10 20 30 40
Δ
R
n
PCR cycle number
Amplification plot
Ct
Figure 3. qPCR amplification plot. This shows the pattern of the signals from probes. Detected 
fluorescent intensities were adjusted by substraction to noise level intensities (ΔRn), which is 
shown in y axis in log scale. The dotted line indicates a selected threshold and the arrow points 
Ct value for the sample that had the largest number of target DNA fragments..  
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Figure 3.  
Two kinds of quantification are usually performed with qPCR, absolute and relative 
quatifications. The intermediate steps in both methods are identical. The difference is 
that the absolute measure requires samples for which the quantity is known. For the 
relative quantification, the samples for which the concentration is high enough for the 
use of sequencial dilution is necessary. One of the common methods used to convert 
measured Ct to the quantity of cDNA molecules is by comparison with a standard 
curve, which is created by conducting identical experiments with known quantities in 
absolute or relative values [38]. Since the linear relationship between the log of the 
quantity of cDNA and Ct is expected, the observations are plotted in a standard curve. 
The linear equation of a trend line is then applied to estimate the quantities of unknown 
samples [39].  
In the extraction step of mRNA from biological sample, the variation of the real 
quantity in various concentrations cannot be avoided. In order to adjust the difference, 
mRNA expression measurement of target genes are commonly accompanied with a 
reference gene, which is assumed to be expressed constantly in a cell. The candidates 
are usually housekeeping genes such as β-actin, 18S rRNA, GAPDH. Among them, the 
expression GAPDH showed less deviation across the combined samples of AD patients 
and controls [40]. 
 
4.3 MICROARRAY FOR GENOME-WIDE EXPRESSION PROFILING 
A microarray-based technique to simultaneously measure the expression of the 
transcripts of multiple genes was developed about 15 years ago, and was created with 
the ultimate goal of being able to measure the complete transcriptome of biological 
samples [41-43]. The measurement is performed by capturing labeled cDNA sequences 
in the sample by hybridization to complementary oligonucleotide probes aligned in an 
array and attached to the solid surface of the microarray (or chip as it is sometimes 
called). Signal detection is then carried out usually with fluorescent labels with a 
scanning laser. The signal intensity represents the abundance of the corresponding 
mRNA in the sample. The technology involves numerous processes from the 
fabrication of the chips themselves to reading and interpreting the signal that induces 
errors to the final output, and high reproducibility is still a major goal of those involved 
in further developing the technology. Thus, appropriate normalization of the data is a 
key requirement [44]. 
 10 
5 CANDIDATE GENE OR PATHWAY APPROACH 
5.1 CANDIDATE GENE OR PATHWAY ASSOCIATION STUDIES 
Candidate gene association studies were very popular before the advent of genome-
wide association studies, essentially representing the only means given technological 
restraints of genotyping biological samples. Candidates were typically (and still are) 
selected based on the previous findings of other biological studies that implicate a 
particular gene in a disease under study. The genetic variant(s) to be genotyped are 
usually chosen according to a prioritizing scheme of the individual study. Candidate 
gene studies often use the validated assay that were specially designed for the target 
marker and could be performed in the researchers own lab or in the laboratories of 
close collaborators. For the candidate pathway approach, which represents a middle 
ground between single gene association studies and the GWAS and may involve 
thousands of SNPs, users tend to turn to genotyping platforms for user selected SNPs 
that are commercially available. 
 
5.2 INSULIN DEGRADING ENZYME (IDE) 
Insulin degrading enzyme (IDE) is a zinc metalloprotease which has been shown to 
have the capability of degrading a variety of small proteins including insulin, insulin-
like growth factor-2 (IGF-2) and amyloid β [45,46]. The gene has received 
considerable attention as a putative candidate in the etiology of Alzheimer disease due 
its strong biochemical activity in being able to degrade the hallmark peptide, amyloid β, 
Figure 4. Identified mRNAs of the IDE gene and the conserved exons among placental 
mammals displayed by UCSC genome browser [1,2]. The second half of the longest transcript 
variant of IDE (NCBI Reference Sequence: NM_004969.3) including the 15
th
 exon is only 
shown here. A scale bar, chromosomal position, and a couple of known transcripts in NCBI 
RNA reference sequence collection(RefSeq) are displayed above human mRNAs from 
GenBank of NIH. Accession numbers of mRNA are shown on the left. Exons were drawn in 
blocks, while lines and arrows represent introns and direction of transcription, respectively. The 
browser was accessed on 2010-09-29. 
15
th 
exon 
   11 
that is considered to play a causal role in Alzheimer disease. Additional evidence 
possibly connecting IDE to AD was obtained from genetic linkage studies showing the 
linkage to chromosome 10q [47], more precisely the 10q23-q25 region that includes 
IDE. Further studies also obtained evidence of linkage of Aβ42 level in plasma to this 
same 10q region [48].  
 Several splice-form variants of the mRNA sequence of IDE have been identified thus 
far (Figure 4). In terms of gene location, this diversity can be observed in the form of 
different transcription initiation sites, variable lengths of the 3‟UTR, and alternative 
versions of the 15th exon, for which numbering is derived by counting along the 
longest splice-form that is composed of 25 exons, NM_004969. The alternatively 
spliced form of transcript at the 15th exon which had been initially identified only in 
testis samples, was also observed in brain (cerebral cortex and cerebellum). The 
isoform translated from the transcript including the 15b exon was shown to have less 
activity in the degradation of Aβ40 and Aβ42 , again supporting the possible role of IDE 
in the development of AD, and providing evidence that splice-form variation might be 
a contributing factor [49]. In another study, an alternative initiation site of translation 
was observed, which can putatively lead to the protein being trafficked to the 
mitochondria by using a specific targeting sequence located in the 5‟ end of the protein 
[50].  
 
5.3 CHOLESTEROL METABOLISM PATHWAY 
Cholesterol plays an important role in maintenance of plasticity and function of neurons 
[51]. Several studies have shown that high cholesterol level in serum or plasma is 
associated with susceptibility to Alzheimer‟s disease (AD) [52,53]. An increased in the 
degree of influx and efflux of cholesterols over the blood-brain barrier in AD patients 
has also observed [52,54]. One of the most important proteins that are involved in 
cholesterol transport in the brain is apolipoprotein E (APOE), of which genetic 
association with AD is well established [55]. APOE also strongly affects amyloid β 
(Aβ) deposition in the brain [56], suggesting a connection between Aβ, the main 
component of plaques, and apolipoprotein metabolism. In further support of this, 
another prominent phenotypic effect of APOE variation is upon cerebrospinal fluid 
(CSF) levels of the 42 amino acid fragment of amyloid β (Aβ42) [57].  
 12 
6 PATHWAY APPROACH USING GENOME-WIDE DATA 
6.1 GENOME-WIDE ASSOCIATION STUDY 
Until only a few years ago, most genotyping methods were designed to read a single or 
perhaps only a handful of SNP markers [58]. The cost of the experiment reagents, time 
required for preparation/labour, and the quantity of DNA required for genotyping 
multiple SNPs were all proportional to the number of markers that were to be tested. 
Limited resources and technologies constrained genetic association studies to be 
performed only with a finite number of markers around intriguing regions typically of 
single candidate genes, on the basis of previous molecular biological evidence and/or 
linkage study results [58,59]. Assisted by this prior knowledge, many genetic markers 
around the putative genes were claimed to be associated with diseases of interest by 
such approaches [6,60]. But, since this relied on testing a fairly limited hypothesis 
(usually one variant in a large gene and usually conducted one gene at a time), many of 
the studies that attempted replication simply failed to observe the earlier claimed effects. 
Even for the few replicated loci, the general theme was that the discovered variants 
simply could not explain substantial fraction of genetic risk of common diseases, such 
as diabetes and Alzheimer disease. The explanations the research community proposed 
were lack of statistical power and a general sense that perhaps traits, the development 
of which result from multiple genetic components interacting together with numerous 
environmental factors, were just too complex [6,59].  
One proposed solution was to turn to high-throughput strategies to test the entire 
genome in the search for genetic association, a natural extension from the earlier 
successes from linkage studies, but taken to the level of common genetic variation. 
Overcoming this tremendous logistical obstacle, the first study was attempted to test 
associations between a complex disease and SNPs across whole human genome 
without targeting specific genes using a newly developed high throughput genotyping 
technique [61,62]. Thus, with the availability of the microarray technology for SNP 
genotyping, it has become commonplace to acquire the genotypes of hundreds of 
thousands of SNPs [63,64]. The method has since been perfected and at present 
requires relatively short experiment time and small quantities of DNA samples. To date 
more than 400 diseases and traits have been tested, the results of which can be readily 
surveyed in „A Catalog of Published Genome-Wide Association Studies‟ available at: 
www.genome.gov/gwastudies [65].  
All GWAS conducted to date are indebted to the development of bioinformatics 
resources related to the human genome project. One such derivative project however 
that more than any other has facilitated GWAS is the HapMap program [66]. The goal 
of the International HapMap consortium was to achieve dense enough genotyping data 
to produce a haplotype map across human genome [67]. The project found that the 
genotypes of ~300,000 markers were enough to capture ~800,000 common (MAF ≥ 
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0.05) SNPs at the threshold r
2
 ≥ 0.8 across whole genome of European samples that 
were proved to be polymorphic in phase I of the project [17]. Based on that study and 
following studies, commercial microarray-based technologies have been designed to 
capture most of known common SNPs across human genome in a single chip [64,68]. 
 
6.2 PATHWAY-BASED APPROACH 
Unlike classic genetic association studies with single target genes and presuppositions 
about molecular mechanisms, genome-wide association studies (GWAS) often entail 
hundreds of thousands of hypothesis tests (often  > 500,000) for association between 
disease status or other phenotype of interest and numerous markers. A very small 
proportion (usually less than 50, ~0.01%) of all the tested markers receives attention 
since most of the others simply fail to pass through the filter that controls the multiple 
testing problems. In addition, in essentially all cases, identified loci also exhibit small 
effect sizes and together only explain a small fraction of the total trait variance [69]. 
Thus, the “pores” of the selection filter are often extremely small to ensure that refined 
test results contain only true positives that can then be replicated in additional samples. 
The standard paradigm is thus to conduct an initial GWAS in a small sample and then 
attempt replication of a handful of markers in much larger populations. From gene 
expression studies, specific gene-oriented questions could be phrased about a disease 
under study, but researchers quickly turned to questions about broad biological themes 
that could be seen in the transcriptome-based results. Thus, as an alternative approach, 
employing prior knowledge about genes with similar functions (pathway) was proposed 
to be applied to GWAS, since the data structure has much in common with the earlier 
expression-based studies [70].  
 
6.3 PATHWAY DATABASES 
6.3.1 Gene Ontology 
The Gene Ontology (GO) project represents a cooperative effort pursuing formalized 
vocabularies of gene products stored in separate databases for various organisms [71]. 
The project was initiated to assist biologists in finding biological roles of unknown 
genes of which sequences were conserved in different organisms. Since it was a 
daunting obstacle that the terminologies were not equivalent in the databases of 
different model organisms, a more standardized dictionary was strongly desired [72]. 
As research at the genome scale continued to produced volumes of biological data, 
typically involving thousands of genes, the standardized descriptions of GO attracted 
great attention and concern [73]. At its core, the GO can be used to group multiple 
genes by similarities at different levels. 
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The GO structure is composed of two parts. One is the ontology terms themselves (GO 
ontology). The database includes the relationships between GO terms. The other is the 
links between the ontologies and gene products (GO annotation). GO ontology 
provides systematically structured species-independent terms (ontologies) in the three 
aspects of a gene product, which are “cellular component”, “molecular function”, and 
“biological process”. The “cellular component” indicates where a gene product acts in 
the cell or around the cell, the “molecular function” explains biochemical activity, and 
the “biological process” describes the function of the gene product for the cells, tissues, 
organs, and organisms [71]. The ontologies in each category are linked as nodes in a 
directed acyclic graph form. An example showing terms and relations from a term 
“meiosis” to the root “biological process” are depicted in Figure 5. The logical relation 
between nodes is often called a parent-child relationship, in which the node close to 
root is parent and the distant node is child. 
 There are three different kinds of relationships between ontologies, which are “is a”, 
“part of”, and “regulates” relations [71]. Among them, the “is a” and “part of” relations 
are transitive. For example, if A is a B and B is a C, then A is a C. In those relationship, 
the genes annotated to the child node is the subset of the genes of the parent node [73]. 
As an example in the Figure 5, the genes assigned to “meiosis”, in other words the 
genes which encode the proteins acting in meiosis, function in cell cycle phase. 
The links in GO annotation database are generated by 
curators [71]. GO terms are assigned to genes based on not 
only the experimental but also the computational evidence 
such as sequence similarity with the genes of another 
organisms of which functions have been identified. In 
reality, quite a large proportion of human genes have been 
annotated using information other than raw experimental 
evidence. The GO continues to grow in contents [74]. 
More genes are annotated to more specific function every 
day and the number of annotations with experimental 
evidence is also increasing. The human data last updated 
24 January 2011 contains 18 216 annotated genes. 
 
6.3.2 KEGG pathway 
The KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathway database is the collection of interacting 
information of genes and molecules that has been obtained 
by manual survey of published literature [75]. It has been 
Figure 5. GO ancestor chart 
of the term "meiosis” 
generated by QuickGO [4] 
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designed to complement the information stored in other contemporary databases that 
focus on individual genes or molecules [76].  
 
6.4 PATHWAY ANALYSIS TOOLS 
All tools described here were originally designed for the analysis and interpretation of 
genome-wide expression profile data. Because those were designed around genes, it is 
appropriate and trivial to apply them to the study of genes in the context of GWAS. 
This is the list of tools that have been used in this thesis, but it should be acknowledged 
that numerous other software programs exist that perform similar functions. 
6.4.1 Database for Annotation, Visualization and Integrated Discovery (DAVID) 
DAVID is one of the most popular pathway analysis tools that was designed by 
academics and is freely available. It allows the testing for the overrepresentation of 
gene pathways, making use of gene annotation information stored in about 40 different 
databases. It allows for the use of a unique function termed “functional annotation 
clustering”, which creates a summary of the output that usually includes an extensive 
number of redundant terms. Thus, it provides additional evidence that may implicate 
pathways that are not clear from the analysis of the individual terms. The significance 
of the enrichment is obtained by a slightly modified Fisher‟s exact test [77]. 
6.4.2 Gene Set Enrichment Analysis (GSEA) 
GSEA, which has been efficiently implemented in JAVA, scrutinizes whether a 
particular pathway is randomly scattered across an input gene list. The gene list is 
sorted by the corresponding significance value for each gene, which typically is 
represented by the negative log of P value for the gene, and this was the primary 
statistic used in this thesis. For each gene in the gene list, it calculates a walking 
enrichment score (ES) that increases when the gene is annotated to the pathway and 
decrease when it is not. The increment is the assigned value for the gene. The final ES 
for the list is the maximum value of walking ES. The statistical significance of ES is 
estimated by permutation. Since multiple pathways are tested, the significance shown 
in output is FDR corrected for multiple testing [78].   
6.4.3 GeneCodis 
GeneCodis is a freely available web application that searches for enriched pathways 
among a subset of genes from a full contingent of genes. It provides a unique function 
to enable to identification of overrepresented combinations of pathways in the separate 
databases, for example, GO biological process and GO cellular component [79]. This is 
comparable to the function provided in DAVID, and also has the goal of providing 
possibly new biological insights that might not be evident from the single term analyses. 
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7 STATISTICAL METHODS 
7.1 ASSOCIATION TEST 
7.1.1 Linear regression 
Often two variables can be expected to be correlated in a simple linear equation. One of 
the obvious examples is the pair of variable consisting of a) travelled distance and b) 
speed in an hour. The relationship can be expressed by a simple linear regression model 
as described: 
            
where    is an explanatory variable (independent variable),   a response variable 
(dependent variable),    the effect (slope parameter),    intercept parameter, and   
random error [80]. Under this model, the random error is assumed to follow normal 
distribution. Whether there exists a true linear relationship or not is tested by the test of 
the hypothesis the effect    is equal to 0, in which the test statistic that follows t-
distribution is often used. 
In genetics, allelic additive effects can be examined in the linear regression model. As 
an independent variable, the number of minor alleles which varies by 0, 1, and 2 is 
commonly used (this also reflects the genotypes of an individual for 0 would represent 
homozygosity for the common allele, 1 heterozygosity, and 2 homozygosity for the rare 
allele). 
When some traits in the experiment (e.g. temperature, experiment date) are suspected to 
affect the response in a linear manner, variables for the traits can be added to examine 
how strongly they influence the general model: 
                      
where    and    are the additional covariates. 
 
7.1.2 Analysis of variance (ANOVA) 
The test for the question „if two or more different groups are same comparing the 
observed values‟ is often performed by analysis of variance (ANOVA), by converting 
the question to „if the values observed in two or more groups are randomly sampled 
from a single normal distribution‟ or „the variance between the groups is significantly 
larger than the variance within each group‟. Practically, it tests the null hypothesis that 
the means of each group are identical. Thus, if the number of groups is larger than 2, 
rejecting the null means that there was significant inequality of means between any pair 
of groups. 
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There are a few assumptions in ANOVA to be considered in its general application. 
One is the errors of observations should follow a normal distribution and be 
independent from the errors of the other observations. One example that is not under 
the latter assumption is the error increase along with the prolonged usage of a single 
machine. The other assumption is that the variances in each groups should not differ by 
a large margin.  
 
7.1.3 Logistic regression 
Logistic regression is often applied to the questions that involve a binary response in 
contrast with simple linear regression. The model is expressed: 
    
      
        
          
where        is the probability of one state of response and the other variables are 
same in 7.1.1. The association is tested with the null hypothesis,     . The P-value of 
the test is obtained by a Wald test or Likelihood ratio test. The logistic model is one of 
the generalized linear models. It can be flexibly adapted to include more traits of 
interest by adding the terms for the traits like linear regression. 
The estimate for β1 in this model especially with binary explanatory variable represents 
the log of odds ratio (OR), which is often interpreted as relative risk with the implicit 
assumption that the outcome is rare. 
 
7.1.4 Chi-square test (Contingency table) 
When two variables of interest are categorical, contingency tables can be created. 
Within the table, the association between the variables is tested assuming the 
independence between the two. Comparing expected values under the assumption and 
observed values in the table, a Pearson‟s test statistics is calculated: 
    
      
 
         
 
where O is observed frequency and E is expected frequency in the table. The    
follows χ2-distribution [81]. This test is not appropriate when the number of samples is 
too small. In such cases, Fisher‟s exact test should be applied, which is explained in the 
section 7.4.1.  
 
7.1.5 Multinomial logistic regression 
With a specific application to the study of human longevity, unlike many other methods 
used to test genetic association, of which explanatory variables are genotype or allele, 
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this model inverted the question (variables) by examining genotype frequency change 
as a function of advancing age. The model is expressed: 
   
       
      
   
                              
                     
  
                                       
where x is age, w indicates the number of alleles (2 for bi-allelic SNP) and         is the 
frequency of genotype i, j at age x [82].  
 
7.2 NORMALITY TEST 
7.2.1 Kolmogorov-Smirnov test 
The Kolmogorov-Smirnov addressed the question of if the underlying distributions of 
observed values in two groups are identical without any parameter in model when the 
values are continuous. Selecting normal distribution as a reference, the test can be used 
to check how well the observations fit to the normal. Since the formula for the 
Kolmogorov-Smirnov statistic takes the maximum distance between two distribution 
functions, the test results can be influenced by outliers [83,84]. 
  
7.2.2 Shapiro-Wilk W test 
The Shapiro-Wilk test checks whether the distribution of a variable is normal [85]. The 
W test statistic has typically been shown to have better performance than the 
Kolmogorov-Smirnov statistic [86,87]. 
 
7.3 MULTIPLE TESTING PROBLEM 
7.3.1 Bonferroni correction 
This method is based on the Bonferroni inequality (or Booles inequality), which states 
that the probability that at least one event is true is equal to or smaller than the 
summation of all probabilities that each event is true [88]. Bounded by the inequality, it 
is enough to declare the association significant when there were multiple hypothesis 
tests and the estimated P-value was not greater than the significance threshold (usually 
named α level) divided by the number of tests. 
If the multiple tests were independent each other, the Bonferroni method is appropriate. 
However, in most cases (especially genetic association tests), they are more or less 
correlated since LD creates extensive correlation between variables. Thus, the 
correction is too stringent, which may result in many false negatives in the studies. 
There are thus special requirements to resolve this problem in genome-wide association 
studies that typically entail in excess of 500,000 tests. 
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7.3.2 False discovery rate 
The false discovery rate is the estimated proportion of the truly negatives among the 
findings declared positive at a particular threshold. It is a useful method to estimate 
how many false associations are included among the declared positives acquired by 
large scale multiple tests such as those included in GWAS [89,90].  
 
7.4 ENRICHMENT TEST 
7.4.1 Hypergeometric test (Fisher’s exact test) 
The hypergeometric probability calculates the probability of observation of a particular 
combination of subsets from the full set of objects classified into two or more different 
classes. For example, it calculates the probability to observe two black and three white 
balls when 5 balls have been picked without replacement from a covered container that 
contains 20 black and 10 white balls. Since the question of enrichment is same as that 
of the hypergeometric, it is often used to check overrepresentation by calculating a P-
value [91]: 
           
 
 
 
  
   
   
 
 
 
 
 
 
   
 
where  
 
 
  is the number of possible combination of b different objects when the 
number a has been picked. In terms of genetics application, there are x genes assigned 
to a pathway within the selected group of K genes. In total there are N genes. The 
pathway contains M genes. 
 
7.4.2 Mann-Whitney U rank test 
The Mann-Whitney U test (or Wilcoxon rank-sum test) is the non-parametric test to 
explore for evidence that the values in two groups are drawn from the populations with 
different distributions [92-94]. The underlying assumption is that the values are 
independent and continuous. It derives the test result by comparing the ranks of the 
components in two testing groups. 
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8 ALZHEIMER DISEASE AND AGING 
8.1 ALZHEIMER DISEASE (AD) 
Alzheimer disease (AD) is the most common cause of dementia in the elderly 
worldwide. Both dementia and AD are rather common and their prevalences increase 
exponentially with advancing age [95-98]. In contrast to broadly defined dementias, the 
slope for AD prevalence is somewhat steeper [97,98]. [97,98]. The prevalence of 
dementia in the age group of 65-69 is about 1%. It exceeds 5% in the group of 75-79 
and continues to increase [99]. A recent study showed that about 40% of individuals of 
the age of 90 or more suffer from dementia and of these, approximately 75% of had a 
more strict AD diagnosis [98]. As the expected lifespan gets higher around the world, 
the number of AD patients is expected to surge [99]. AD sufferers require considerable 
care due to the chronic nature of the disorder, which will be even a more serious burden 
to the individuals themselves and families in the coming decades [100-102].  
Clinically, AD is characterized by a progressive cognitive and functional impairment. 
Neuropathologically, it is discriminated by two lesions, “plaques” and “tangles”. The 
first is the aggregated amyloid-β (Aβ) peptide observed in the extracellular matrix of 
brain tissue. The second is the neurofibrillary depostion of hyperphosphorylated τ (tau) 
protein in the intracellular matrix [103]. Genetically, it is classified into two forms, 
early-onset familial AD (EOFAD) and late-onset AD (LOAD) by the patient‟s age 
[104]. The latter is much more common (95% of all cases) and does not show as 
obvious familial segregation as EOFAD does.   
 
8.1.1 Amyloid-β in AD 
The amyloid-β peptide is generated by the cleavage of amyloid-β precursor protein 
(APP) by β-secretase APP-cleaving enzyme (BACE) followed by γ-secretase cleavage, 
competing with an alternative non-amyloidogenic pathway that begins with cutting 
APP by α-secretase activity [105,106]. Consistent with the Aβ genesis pathway, 
mutations in the genes of APP, presenilin 1 (PSEN1) and presenilin 2 (PSEN2)  induce 
EOFAD with full penetrance [107-109], where the presenilins are highly homologous 
genes encoding one of four components of γ-secretase complex [110]. In the brain of 
healthy individual, the Aβ of which neurotoxicity is observed [111,112] is degraded by 
the insulin-degrading enzyme (IDE), neprilysin, endothelin-converting enzyme (ECE-
1), and angiotensin-converting enzyme (ACE) [113-115]. It is also eliminated by the 
efflux mediated by low-density lipoprotein receptor-related protein from the brain 
[110,116]. Under the Aβ hypothesis, an imbalance that disturbs the equilibrium status 
between production and clearance is thought to be a core mechanism that leads to the 
development of AD [105,110,117].  
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8.1.2 Genetic studies on late-onset AD 
The patients that suffer from both LOAD as well as EOFAD forms of AD are usually 
clustered in families, even if EOFAD carries “familial” in its definition since it is 
transmitted in a strict Mendelian manner. EOFAD is rare, with only about 1% or less of 
the AD population having an onset before the age of 65 (the typically threshold used to 
define early and late onset forms). About 60-80% of LOAD been shown to be 
determined by genetic factors, showing that there is an extensive genetic component, 
much of which is still unknown [95]. Towards the discovery of genetic variants that 
account for the late-onset form of AD, genetic association studies have over the past 
two decades primarily focused on putative candidate genes, defined subjectively by 
their possible involvement in biological processes thought to be of relevance to 
dementia. For instance, many of the investigated candidates over the years have been 
Figure 6. Manhattan plot of the recent genetic association data on the AlzGene database 
(http://www.alzgene.org. accessed on 2010-09-27)[5]. A total of 2033 genetic variants are 
shown here. The results from meta-analyses of 4 or more independent data sets are shown in 
green dots. The results from single-studies or meta-analyses of less than 4 separate studies are 
shown in black or gray dots. Note that the dot for APOE should be much higher in the plot, 
since P-value < 1×10
-50
.  The dark columns indicate the locations that showed “genome-wide 
suggestive” evidence of linkage in a meta-analysis of linkage studies on LOAD. The light 
columns are for “genome-wide nominal” evidence. Genes in blue at the bottom are those 
associated with EOFAD.  
Reprinted from Neuron, 68, L.Bertram, et al., The Genetics of Alzheimer Disease: Back to the Future, 
271, Copyright (2010), with permission from Elsevier 
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the genes that encode proteins that involved in the metabolism of Aβ. Despite these 
efforts, before the recent era of GWAS, only a single non-synonymous (amino-acid 
changing) SNP in Apolipoprotein E (APOE) had been confirmed that was associated 
with LOAD, replicated extensively by multiple research groups and in multiple human 
populations since it was discovered in 1993 [104,118]. For the large number of other 
candidate gene studies that claimed association of their target genes with AD, 
essentially all have failed to be replicated in following studies in independent 
populations. 
Following the technical developments necessary to facilitate genome-scale association 
studies, a few GWAS on AD, more precisely LOAD, with large samples from various 
world populations have been conducted, and the summary of these is presented in 
Table 1. Up until the writing of this these, in total 14 studies have been published, of 
which three analyzed relatively large samples derived from more than 2000 cases and 
comparable controls in their primary analysis. By such extensive efforts, the 
associations of the genes PICALM, CLU, CR1, and BIN1, together with the well-known 
APOE, have been reliably replicated in multiple studies. As an overview, the 
significances of all the markers in the meta-analyses for AD available from the 
AlzGene database [5] are illustrated in Figure 6 [104]. Supporting some of the findings, 
the results from genome-wide linkage studies are included in the illustration with gray 
columns. Despite the successes, it should be noted that the estimated effects of the 
replicated loci excluding APOE were still low (allelic ORs ~1.15 referring to OR ~4 for 
APOE ε4) [104].  
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Table 1. Description of overall GWAS in AD on AlzGene database  
GWAS Design Population No. SNPs 
No. AD GWAS 
(Follow-up)
b
 
No. CTRL GWAS 
(Follow-up)
 b
 
“Featured” Genes
a
 
Grupe et al., 2007[119] Case-control USA & UK 17,343 380 (1428) 396 (1666) 
APOE, ACAN, BCR, CTSS, EBF3, FAM63A**, GALP, 
GWA_14q32.13, GWA_7p15.2, LMNA, LOC651924, MYH13, 
PCK1, PGBD1, TNK1, TRAK2, UBD 
Coon et al., 2007[120] & 
 
Case-control 
USA, 
Netherlands# 
502,627 446 (415) 290 (260) APOE, GAB2 
Li et al., 2008[122] Case-control Canada & UK 469,438 753 (418) 736 (249) APOE, GOLM1, GWA_15q21.2, GWA_9p24.3 
Poduslo et al., 2009[123] 
Family-based 
&Case-control 
USA 489,218 9 (199) 10 (225) TRPC4AP 
Abraham et al., 2008[124] Case-control UK‡ 561,494 1082 (-) 1239 (1400) APOE, LRAT 
Bertram et al., 2008[125] Family-based USA 484,522 941 (1767) 404 (838) APOE, ATXN1, CD33, GWA_14q31 
Beecham et al., 2009[126] Case-control USAˆ 532,000 492 (238) 496 (220) APOE, FAM113B 
Carrasquillo et al., 
2009[127] 
Case-control USA● 313,504 844 (1547) 1255 (1209) APOE, PCDH11X 
Lambert et al., 2009[128] Case-control Europe‡ 540,000 2035 (3978) 5328 (3297) APOE, CLU (APOJ), CR1 
Harold et al., 2009[129] Case-control 
USA & 
Europe●‡ 
610,000 3941 (2023) 7848 (2340) APOE, CLU (APOJ), PICALM 
Heinzen et al., 2009[130] 
(CNV) 
Case-control USAˆ n.g. 331 (-) 368 (-) APOE, CHRNA7 
Potkin et al., 2009[131] Case-control USA (ADNI)† 516,645 172 (-) 209 (-) APOE, ARSB, CAND1, EFNA5, MAGI2, PRUNE2 
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GWAS Design Population No. SNPs 
No. AD GWAS 
(Follow-up)
b
 
No. CTRL GWAS 
(Follow-up)
 b
 
“Featured” Genes
a
 
Seshadri et al., 2010[132] Case-control 
Europe & 
USA●‡# 
2,540,000 3006 (6505) 22604 (13532) APOE, BIN1, CLU (APOJ), EXOC3L2, PICALM 
Naj et al., 2010[133] Case-control 
USA & 
Europe†#ˆ 
483,399 931 (1338) 1104 (2003) APOE, MTHFD1L 
The data was achieved from AlzGene database [5] on 2010-09-27. 
a 
the genes affirmed to be associated with AD by the authors for the original study. 
The genes in bold font are those that showed study-wide “genome-wide significant” association. b follow-up study data set. The symbols (●,‡,#,†,ˆ) 
indicate there are common samples in different studies. Note that the well-known genetic variants in APOE were in many studies acquired by genotyping 
the proxy SNPs. 
Reprinted from Neuron, 68, L.Bertram, et al., The Genetics of Alzheimer Disease: Back to the Future, 271, Copyright (2010), with permission from Elsevier 
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8.2 AGING 
Age is the single most important factor in AD development. Upon neuropathological 
examination, normal individuals at advanced age may exhibit evidence of 
neurodegeneration, but at a level considerably more mild than AD patients undergo 
[134]. As the brain ages, various type of cognitive decline are typically observable, 
such as a reduced memory capacity, slowed response to external stimuli [135], and 
diminished creativity [136]. However, the knowledge and skills obtained at a younger 
age (typically referred to as wisdom) tend to remain intact for a longer time [137]. 
Microscopically, the number of neocortical neurons decreases by approximately 10% 
through 20 to 90 years while the number of glial cells tends to be invariant [138]. 
Neuronal loss in hippocampus is usually not significant in normal elderly individuals 
[139] whereas severe shrinkage of the hippocampus has been observed in AD cases 
[140]. 
The theories that pursue explanations of aging are numerous [141]. The two central 
branches of these are the “programmed” and “error” theories. The programmed aging 
theories have originated from the serial observations of the limited lifespan of 
explanted human cells [142], the shortening of telomeres that occurs with each 
successive cell cycle [143,144], and DNA damage response (DDR), of which 
accumulation leads cells to apoptosis or senescence [145]. Thus, most cells are destined 
to death due to the existence of a molecular clock at the tip of each chromosome. The 
programmed theory states that aging is controlled by a pre-programmed biological 
clock. The theory is supported by the observations in model organisms, which have 
showed that some mutants have increased longevity [146]. Most of the genes that have 
been mutated in such long-lived organism have been related to the pathways that 
regulate basic cellular functions such as growth, energy metabolism, and reproduction 
[147]. The evolutionary existence of programmed aging is explained by two theories of 
“antagonistic pleiotropy” and “disposable soma theory”. The latter posits that lifespan 
is determined by the balance between growth/reproduction and somatic maintenance 
[147]. The former describes that the genes that are deleterious in old age remained in 
the genome because those same versions of the genes are beneficial in young age [141]. 
The “error” theory is that a decrease in vitality with advancing age is due to the 
accumulation of environmental attacks such as reactive oxygen species (ROS) in 
mitochondria inducing biological damages in cell or organism [148]. 
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9 PRESENT INVESTIGATIONS 
9.1 AIMS 
 To investigate the association of genetic markers in IDE with age and with 
molecular levels in intermediate biological processes 
 To examine the association of genetic variants of the genes in the cholesterol 
metabolism pathway 
 To identify the biological pathways that are overrepresented among genes 
associated with age 
 To develop a bioinformatics tool for pathway enrichment analysis and to 
address emergent issues in the analysis  
 To identify pathways that are enriched among genes associated with Alzheimer 
disease 
 
 
9.2 PAPER I 
9.2.1 Materials and Methods 
Human samples are briefly described in Table 2. Detailed descriptions of some of the 
samples are available in Ulrika K. Eriksson‟s thesis [149] and the original publications 
contained therein. 
 
Table 2. Brief descriptions of human samples 
Sample Sample Size (M/F) Origin Description 
Sample 1 601 (290/311) Swedish AD-free controls (Harmony) 
Sample 2 321 (116/205) Australian PD-free controls 
Sample 3 724 (411/313) Swedish Non-diabetic controls 
Sample 4 178 (77/101) Swedish AD-free controls 
Sample 5 539 (181/358) Swedish Random Population (OCTO) 
Sample 6 590 (249/341) Swedish Random Population (SATSA) 
Sample 7 2703 (1862/841) Swedish MI case-control 
Sample 8 40 (14/26) Swedish Sequencing 
Sample 9 178 (83/95) English DNA/RNA Brain 
M = male, F = female.  
Sample size represents the total sample for which genotyping was performed. 
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Genotyping of SNPs was conducted with dynamic allele specific hybridization (DASH) 
[150]. The novel spliceform of IDE was identified by PCR with a primer pair targeting 
both 15a and 15b-exons. The quantification of three different spliceforms was 
performed by qPCR using fluorescent labelled probes and exon-boundary spanning 
primers. The reactions were run in duplicate, and Ct values were averaged. Sequencing 
for identifying novel polymorphism was performed using a standard capillary 
electrophoresis method.  
Multinomial logistic models were used to investigate the dependency of genotype on 
age [82]. The age difference between genotype group was assessed by ANOVA. Cox 
models were applied for the survival analysis of samples 5 and 6. Expression level 
analysis was performed using ANOVA with Ct values. HWE was tested with a χ2 
statistic. Normality was assessed using a Kolgomorov-Smirnov test.  
 
9.2.2 Results 
Among tested markers, the SNPs, rs1887922 and rs2251101 were uniformly associated 
with the observed traits in only men across the different populations. Intriguingly, 
heterozygotes comparing to homozygotes regardless allele itself had significantly lower 
age-at-sampling, shorter life span, higher insulin levels in plasma, and higher mRNA 
expression in brain. The association of both markers with age-at-sampling of men from 
4 different samples was significant (P=2.2×10
-7
 and 5.1×10
-5
), contrasting no evidence 
of association in women. The survival analyses with two sample groups showed 
significantly different mortality across the genotype classes of rs1887922 and 
rs2251101 with both the COX model and ANOVA, respectively. The genotype 
frequency of rs1887922 between young and old sample groups was significantly 
different (P=0.0052), but not for rs2251101 (P=0.17). Increased mortality among 
heterozygotes was observed in another sample for both markers (P=0.0064, 0.018). 
Genotypes of rs2251101 in men was strongly associated with insulin levels in plasma 
that were obtained at a 10 year interval. This marker was significantly associated with 
both the 15A and 15B spliceform expression levels (P=0.014, 0.0032) 
 
9.3 PAPER II 
9.3.1 Materials and Methods 
The samples used in this paper were 1567 Swedish dementia cases and 2003 controls 
from four aging twin studies (SATSA, OCTO-Twin, GENDER, HARMONY) and a 
non-twin Alzheimer disease case-control study. The descriptions of the samples in 
more detail can be obtained in the previous publications for individual studies [95,151-
154] and in Ulrika K. Eriksson‟s thesis [149]. For the secondary analyses, the genotype 
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data of Swedish males from the CAPS(Cancer Prostate in Sweden) and the expression 
data from two previous studies were obtained [155,156].  
The 25 genes in cholesterol metabolism pathway were selected by literature search. 
Prioritizing the markers with previous finding, functional candidate, and LD, in total 
506 SNPs in those genes were chosen and genotyped to investigate the association with 
dementia. CSF samples were obtained in Swedish AD case-control study [157].  
HWE was tested with Pearson χ2 statistic. Initial association tests between individual 
markers and dementia were conducted using logistic regression. Alternating logistic 
regression was applied to account for pair dependency of twins [158]. For the network 
analysis, FunCoup was employed [159]  
 
9.3.2 Results 
Among the observed marker, rs2230805 in ABCA1 showed the most significant 
association following the APOE genetic variant. The third markers was located close to 
SREBF1 (P=8.5×10
-6
) , which is in a large LD block spanning 7 genes. Applying F-
SNP database tool, we found two potentially functional markers in high LD with the 
associated marker near SREBF1. Further investigating the association of gene 
expression with proxy SNPs of the SREBF1 marker produced one strong correlation 
between genotype of the proxy and ATPAF2 expression trait. In the network analysis, 
only TOM1L2 could build a network with well known AD genes among the seven 
genes.  
 
9.4 PAPER III 
9.4.1 Materials and Methods 
The first sample set consisted of 191 individuals who were free from neurological 
disease and whose brain tissues were collected at autopsy after deaths at ages 65-100. 
The second samples consisted of 1240 individuals at the ages of 15 to 94 years. The 
detailed descriptions of the human samples and the expression measurement protocols 
in detail are provided in the original paper [156,160]. 
After outlier removal by the Šidák‟s method, the associations between age-at-death and 
log transformed expression levels of brain samples were examined for brain samples by 
a linear regression model with global expression as a covariate. For the lymphocyte 
samples, similar linear regression model without a global expression term was applied.  
For the pathway analyses, DAVID was applied to test the overrepresentation of Gene 
Ontology terms or KEGG pathway descriptors among the associated genes with 
advancing age [72,76,77].  
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9.4.2 Results 
For the brain sample, the linear regression of 14 078 individual transcripts produced 54 
significantly associated genes with age-at-death adjusted by the Bonferroni method. A 
validation of the association was confirmed by comparing the 54 genes with the genes 
identified in a previous study [161]. By pathway analysis of the associated genes 
(unadjusted P<0.05) with age, „mitochondrion‟, „synaptic transmission‟, and several 
more terms in GO were observed to be enriched among negatively correlated genes, 
and „DNA binding‟, „regulation of transcription, DNA-dependent‟, and more term in 
GO were identified among positively correlated genes. 
Applying same strategy to additional samples of lymphocytes, the linear regression on 
each of 19 648 individual transcripts versus age produced a gene list of 1080 (612 
negative, 468 positive) significantly associated transcripts. Dividing this list into 
positive and negative groups of genes as was done in the brain study, pathway analysis 
was performed with the top genes (unadjusted P<0.01). The terms„mitochondrion‟, 
„nucleic acid binding‟, and several others were enriched among the negatively 
expressed genes and „plasma membrane‟, „signal transduction‟ and several additional 
weaker terms were overrepresented among the positively regulated genes. In the gene 
architecture comparison study, the negatively associated genes had significantly smaller 
intron to exon length ratio.  
 
9.5 PAPER IV 
9.5.1 ProxyGeneLD.pl 
The program was designed to automate the processes of assigning each tested SNP 
marker to genes and to subsequently compute and assign gene-wide P-values. 
Considering the correlation structure among the SNPs (Linkage disequilibrium; LD), 
markers have the potential to be assigned to genes which are located far from them in 
terms of genomic distance. This is an important characteristic of the program in that it 
reflects the fact that a single marker can be assigned to multiple genes, each of which 
could contribute to a disease. The software was specifically designed to also take into 
consideration the inflation of significance due to multiple single marker tests in the 
calculation of P-value for each gene. 
The process begins with investigating the LD structures using analogous populations 
with denser genotyping data. In this thesis, all analyses employing this program 
adopted HapMap CEU data. The software then continues to read the genetic marker 
lists derived from a genome-wide association study, with the core input being the P-
values (usually generated from a simple allele test between cases and controls). All the 
tested markers are assigned to the genes based on genomic position. The markers 
within a region of a 1kbp upstream from 5‟end in the direction of transcription but not 
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including any sequence downstream of 3‟end of the longest known splice variant of a 
gene are assigned to the gene in this thesis. This parameter is readily adjustable by a 
series of command line options. On the grounds that the SNPs that are not genotyped 
but are strongly correlated with typed SNP (proxies) can be inferred from the observed 
markers [21], the typed markers are assigned to the genes of their proxies. In order to 
adjust P-value to account for the length of the gene and marker density spanning each 
gene region, the program counts the effective number of markers which can be 
regarded as independent genetic variations assigned to same gene. The numbers are 
then multiplied by the lowest P-values of the markers assigned to the genes. An 
example to illustrate the processes is shown in Figure 7. 
The Perl programming environment was chosen as the language to build this program. 
Perl has excellent functions dealing with text-related manipulation compared with other 
popular programming languages such as JAVA, C++. Importantly, a single run of 
ProxyGeneLD per GWAS was generally regarded as sufficient, since the only 
parameters that change the output are the boundaries that define gene regions and LD 
cut-off thresholds, both of which were standardized. So, running time, the greatest 
limitation of Perl is not a serious obstacle. A standard run of the software on a GWAS 
with perhaps 500,000 SNPs might take on the order of 15 minutes on a standard PC.  
In order to find the best gene identifier for the following analysis after running this 
program, several gene identifiers in different databases were tested. We compared how 
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Figure 7. The illustration of how the program calculates gene-wide P-values with an artificial 
example. There are two genes and 8 SNPs of which six are genotyped in this study and two are 
proxies. Four SNPs on the left of the figure are in high LD and so are the three on the right. P-
value for each genes are computed by the following formulas. 
P-value for Gene1 = min(0.02, 0.01, 0.02) × 1 (the effective number) = 0.01 
P-value for Gene2 = min(0.02, 0.25, min(0.1, 0.09)) × 3 = 0.06 
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many genes could be recognized by DAVID. Among the tested identifiers, GeneID of 
NCBI Entrez performed best and was selected as the standard identifier in the processes 
and output of ProxyGeneLD.  
 
9.5.2 Pathway analysis 
Three different applications were employed to find overrepresented pathways among a 
subset of a gene lists against full set. One of them was gene set enrichment analysis 
(GSEA) [78]. It (GSEA v2.0) was applied with slight modification of the output of 
ProxyGeneLD, since it requires a weight for each gene instead of a P-value, which was 
calculated by negative log of adjusted gene-wide P-value on the basis of 10. When 
negative weights appeared due to the gene-based adjustments, entire weights were 
adjusted by shifting to all positives and single zero. The application ran with 5000 
permutations.  
Another application was the database for annotation, visualization and integrated 
discovery (DAVID). The analyses in paper IV were performed with a March 2008 GO 
annotation update. The other was the Ingenuity pathway analysis (IPA; Ingenuity 
Systems), which is a commercial web-delivered application with its own annotation 
database.  
 
9.5.3 Materials and methods 
The resultant data from genome-wide association studies was obtained from the four 
different previous studies of Willer et al., 2008 [162], Zeggini et al., 2008 [163], Barrett 
et al., [164] and Aulchenko et al., 2009 [165]. The analysis of gene ranks was 
performed with the Mann-Whitney U test. 
 
9.5.4 Results 
To investigate the bias introduced by gene length, pathway analysis of one GWAS 
dataset was performed using ProxyGeneLD and DAVID. The overrepresented terms 
among the genes with high unadjusted P-value were similar to the enriched terms 
among the longest genes. To observe local clustering of functionally similar genes, 
taking equally distributed blocks along every chromosome, enrichment statistics were 
recorded. The observation revealed that there exists such clustering, which should be 
taken into account in any pathway analysis. To examine if study results can be 
influence by imputation, we compared the pathway analysis results that were 
performed with imputed marker data and non-imputed marker data. Most genes 
retained similar rank regardless of imputation, but a few outliers were observed. By the 
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pathway analyses with several real GWAS data, several GO term enrichment was 
observed.  
 
9.6 PAPER V 
9.6.1 Materials and Methods 
We obtained the marker-based results data of the genome-wide association study on 
Alzheimer disease performed with 2032 AD cases and 5328 controls from a French 
population [128]. Applying ProxyGeneLD program, the single marker test results for 
every the SNPs were converted into a list of 16 503 gene-wide P-values. The genes that 
had an adjusted P-value of 0.05 or less were tested for enrichment of GO terms against 
the full set of the converted genes using DAVID [166] and Genecodis [79]. 
Examining the genomic locations of the top genes, we found that four genes of the top 
five are clustered in a large LD block. Applying FunCoup [159], each of the four genes 
(APOE, TOMM40, PVRL2 and BCL3) was tested for connections in a network with the 
genes annotated to the overrepresented GO term found in the pathway analysis.  
 
9.6.2 Results 
By the pathway analysis, „intracellular transmembrane protein transport‟ term in GO 
was found to be overrepresented among genes that were highly associated with AD 
(P<0.05). Since the most significantly associated gene, TOMM40 is located in an LD 
block spanning TOMM40, PVRL, BCL3, APOE, the latter being the most well-known 
AD predisposing gene, a network analysis was performed. Among the four genes, only 
TOMM40 could build a network with the top genes with the identified enriched term.  
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10 DISCUSSIONS 
10.1 METHODOLOGICAL ASPECTS 
This thesis is represented by five studies that have applied three different molecular and 
statistical approaches on different scales; candidate gene, target pathway, and genome-
wide pathway approaches. This change in scale of my studies partially reflects the 
history of genetic association studies in the genetic epidemiology community. There is 
one missing piece to fit the complete history, which is a genome-wide association study 
in our own Swedish samples. Thus, two papers in this thesis deal specifically with 
GWAS data, but we were unable to complete a GWAS in sufficient time to be included 
here. 
The candidate gene study in this thesis identified association of several SNPs spanning 
IDE with age-at-sampling and age-at-death, together indicating the specific genotypes 
of IDE confer increased mortality that can be seen in the population. The study 
proceeded to examine this finding at the molecular level, targeting IDE mRNA 
expression and insulin levels, which are the direct product of the gene and perhaps the 
most important substrate of the protein (IDE), respectively. This represents a fairly 
unique strategy since it is uncommon for genetic association findings to be followed up 
at the molecular level at all. Thus, most researchers tend to only present the nominal 
genetic association statistics with their target disease phenotype. There exist a few 
studies that examine the association of a genetic marker with a “molecular phenotype” 
representing the putative intermediate biological process that leads from genotype to 
disease, in order to support the epidemiological finding [167-169]. However, the 
concept of examining intermediate phenotypes was proposed long ago [170] and 
interestingly, the method is particularly popular in psychiatry studies [171]. The 
strategy at its core is based upon the assumption that the possible mechanism leading 
from genetic variant to molecular phenotype is simpler than the mechanism to explain 
the association at the far end of the scale, the clinically defined disease state [167]. In 
the study on IDE, the association with the various molecular phenotypes provided 
strong support for initial observation at two levels. In the first, obtaining association 
with a molecular phenotype enhances the evidence that gene under study does in fact 
contain functional variation, and is especially meaningful if it is the same genetic 
markers. For the second, the kind of association can lead to insight about the potential 
mechanism, where a genotype that confers increased risk for disease, can be linked to 
either increased or decreased expression, and this in turn tied to how it affects an 
intermediate trait (in our case plasma insulin level). The study on IDE was also 
particularly powerful since we were able to replicate the findings in a number of 
additional samples. 
Candidate gene studies have their own particular advantages. The probes and assays 
designed for a specific gene and markers typically are highly validated. Because cost is 
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usually low and the hypothesis specific, redundant probes can be added to search for 
genotyping errors as well as to consider possibly different LD patterns from the 
population that has been employed for the original design that used either custom 
genotyping technology or a commercial genotyping chip. Put another way, to search for 
a paragraph in a book, we don‟t have to search every book in a library, if we know what 
book may have the paragraph. In retrospect however, the majority of genetic 
association studies that have targeted specific candidate genes have failed to be 
replicated by independent research groups using either further candidate gene studies or 
GWAS [172-174]. One emerging theme from the thriving GWAS community suggests 
the phenotypes that we are typically interested in are associated with multiple variants 
with small effect sizes [69,175-177]. In other words, small phrases of the paragraph 
have been scattered into many books. Thus candidate gene studies have evolved to be 
applied in the validation step of GWAS as shown in Table 1 as „follow-up study‟ 
[6,104]. If an association of a genetic marker has been confirmed, zooming-out of the 
nearby region from that marker, a candidate gene study can be a fruitful avenue to 
genotype the region at much higher marker density using more probes for rarer SNPs. It 
can also be an important guide for sequencing or measuring potential intermediate 
molecular phenotypes [169]. 
The candidate pathway approach is to some extent analogous to the candidate gene 
approach. It has similar pros and cons, especially in comparison with GWAS. One 
application of the method that has to my knowledge not been tested yet is as a 
secondary validating study focusing on the overrepresented pathways found by a 
pathway analysis. Thus, establishing lists of genes from pathway analysis of GWAS to 
perform dense genotyping may be a fruitful avenue to pursue. 
GWAS has been remarkably successful in the identification of predisposing genetic 
variants to a variety of human diseases and traits. However, the effect sizes of the 
associated variants as estimated are typically too small to explain a large fraction of 
heritability of the disease [69,175]. Numerous approaches have been developed to 
resolve this emerging problem [178]. Some of these involve testing a “set” of SNP 
markers [179,180], integrating with linkage studies to enhance evidence [181], and 
analyzing overrepresented pathways [70], the latter being upon which this thesis 
focuses. The putative signals in the multiple marker tests often are confounded by the 
surrounding noise, thus watering down the statistical significance if the investigated 
regions are large. The method also doesn‟t employ any additional information. Studies 
that attempt to incorporate association findings with linkage results require that samples 
are collected under special conditions. In contrast, the pathway approach takes 
advantage of biological knowledge as an additional source of information and is 
applicable to the vast and growing amount of GWAS data directly. 
Pathway-based analyses has been most widely used in genome-wide (transcriptome-
wide) expression profiling studies [182]. As the history of the use of expression 
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microarrays [41] is longer than for the high-throughput genotyping approaches, the 
various tools that have been created have had longer development time and 
consequently been tested extensively [77,78,183,184]. It has only relatively recently 
become possible to test the potential of the strategy to analyze GWAS data [70]. This 
lack of proper tools to handle SNP data for pathway analysis motivated study IV in this 
thesis. The availability of an extensive array of free applications available to explore for 
overrepresented pathways from significant gene lists, enabled the development of our 
tool for the process converting SNP to gene data. 
Paper IV describes in detail how ProxyGeneLD was developed and reflects our general 
satisfaction with the program. We extended the use of the program to another study in 
the paper V specifically targeting Alzheimer disease. In terms of discoveries using the 
software, one of the most important is related to apparent (and false) enrichment of 
longer genes, which has been ignored by some of published papers that included 
pathway analysis strategies. The program also assists in the mapping genotyped SNPs 
to “proxy” genes, which is an area that is still neglected in most association studies 
[178]. One core premise in ProxyGeneLD that may be questioned is that the LD 
structure of a study population is comparable to that of the analogous cohort that has 
denser genotyping data such as HapMap CEU. Thus, the HapMap cohort may not 
reflect the LD pattern of the population under investigation, but it remains the best 
available and is a sufficiently valid surrogate of which data have been considered in the 
design of the commercial genotyping chips [185]. Numerous programs for assisting 
with pathway analysis of GWAS are available at present [178]. One that has recently 
been developed and stands out from the rest is VEGAS [186].  VEGAS adjusts gene-
wide P-values considering LD using a relatively advanced statistical algorithm 
involving permutation, which can be implemented in our program by replacing the step 
of classifying “proxy cluster” with an ad-hoc threshold for high LD (r2>0.8) [186].  
The pathway approach as applied to gene expression results in this thesis demonstrated 
that such data can produce new insight into general biological themes in the transition 
youth to advanced age. There were numerous novel findings including evidence that 
gene structure may influence gene regulation with advancing age, as well as both up-
regulated and down-regulated biological pathways that have not previously been 
observed. One observation, the down-regulation of mitochondrial genes was not novel, 
having been seen on two other occasions [187,188]. However, the successful 
replication of an initial finding providing vastly stronger evidence is an important 
indication of the potential of the approach in paper III that be applied for novel findings 
in future studies. 
The pathway analyses in this thesis were conducted primarily with gene annotation data 
using the GO database. However, it should be noted that the annotation process in GO 
is still incomplete. The number of annotated gene is still growing. Additionally genes 
that have been annotated by the sequence similarity to the genes with known function 
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will be annotated more precisely based on biochemical study results in the near future. 
As GO accumulates more and more annotations, it will likely provide a greater 
opportunity to observe more meaningful pathway discoveries, especially if applied to 
rapidly expanding GWAS data in various human populations. 
 
10.2 BIOLOGICAL ASPECTS 
Each study in this thesis is a distinct entity and together may appear as unrelated 
biological findings. One contributing factor to this is that three out of five studies didn‟t 
have specific hypothesis, involving instead very general concepts such as the study of 
aging or AD. With no specific hypothesis and thousands of tests, the produced findings 
are thus difficult to inter-linked and seen in a unifying context. Thus, many of the 
biological discussions that are related primarily to the individual study are addressed in 
the discussion section of each constituent paper of this thesis. 
The initial biological question of this thesis was “What causes Alzheimer disease in the 
elderly?” Because of the strong correlation between AD and age, the question was 
expanded to include another related scientific question “What is aging?” As a metaphor, 
these concepts can be partially related to the idea from hypothetical analogous research 
on other object, the automobile. If AD corresponds to engine failure, the first question 
will be “What causes engine failure?” As we are generally well aware, it can break 
down for numerous reasons. For example, failure in a shaft, piston, valves, and so on. 
But, a more fundamental cause is simply aging. The broken down components were 
aged chemically or mechanically. For the car, to avoid engine failure, we should 
understand aging first and maintain our cars to lower the speed of the aging. Likewise, 
it is natural that the study of AD should be accompanied by the study of aging itself.  
There are two transcript variants of IDE registered in the NCBI RNA reference 
sequence collection. One is relatively long with ~120kbp of pre-mRNA (the average 
was ~60kbp in paper III). The other is shorter with a ~46kbp long pre-mRNA. The first 
has large ratio of intron to exon length (the ratio is ~32, average was ~21 in paper III). 
The second has a smaller intron to exon ratio of ~10. Taking into consideration that 
premature aging leads to a shorter life span, the observation in Paper III that the 
positively associated genes were compact is consistent with the expression difference in 
the study of IDE assuming the shorter IDE transcript variant was predominantly 
measured. Since the ages of the samples for the IDE expression study were rather old 
(~80 years) and uniform, it can be a possible mechanism that the brain cells of 
heterozygotes, who were not nominally more aged but biologically more aged, 
expressed higher levels of the shorter IDE transcript. 
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11 CONCLUSIONS 
 Pathway analysis applied to genome-wide association studies has the potential 
to produce new biological insights 
 Pathway analysis in genome-wide expression studies is a useful method to 
address general biological questions related to aging. 
 ProxyGeneLD we developed is a useful tool for pathway analysis, especially in 
its ability assign SNP to “proxy” gene with high fidelity. 
 Genetic variants in IDE are associated with age in a manner that may reflect 
changes in mRNA expression and plasma insulin levels 
 Genetic association of an LD block including SREBF1 with dementia. 
 Genes that play a role in mitochondrial function were overrepresented among 
genes that have lower expression levels at advanced age. 
 Negatively associated genes with increasing age tend to be non-compact, 
indicating that gene structure plays a role in the age-dependent regulation of 
transcription. 
 From pathway and network analyses, TOMM40 may play a role in Alzheimer 
disease development. 
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12 FUTURE PERSPECTIVES 
The current version of ProxyGeneLD requires an additional tool such as DAVID to test 
overrepresentation of pathways by retrieving data in the GO or KEGG pathway 
databases. Due to the lack of such a function specifically designed in ProxyGeneLD, 
when genes with similar function are clustered in nearby chromosomal positions, 
enrichment statistics for pathways may indicate spurious findings. The solution 
introduced in paper IV has involved manual exclusion of such genes from the gene lists, 
which is often a tedious process. If the program has a function of directly accessing the 
GO database to enable the calculation of enrichment statistics by itself, then such a 
problem can be resolved by simple modification at the counting step where the number 
of genes is assigned to a pathway. Thus, regardless of how many genes are really 
assigned, the number of the clustered genes, even if SNPs in the genes are in high LD, 
is forced to be counted as 1.  
As shown in Paper I, the investigation of molecular targets for genetic association 
produces evidence that can represent an important corroboration of the epidemiological 
findings. Applying a similar strategy at the genome-wide scale has a great deal of 
potential. Observing association of intermediate molecules in a biological metabolic 
pathway from DNA to RNA, to protein, and eventually to metabolites and disease, can 
provide evidence of the exact molecular mechanism that leads to disease. Investigating 
the association of genetic variants with metabolites (via “metabolomics”) is an ongoing 
project, in which LC-MS and GC-MS were employed to measure thousands of 
metabolites simultaneously. It will hopefully also lead to new biological insights that 
can link known genetic associations to the underlying mechanisms. 
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